Additional Compounds definition

Additional Compounds mean naltrexone and nalmephene/ nalmefene.
Sample 1Sample 2Sample 3
Additional Compounds means magnetic resonance imaging agents other than Blood Pool Magnetic Resonance Contrast Agents.
Sample 1Sample 2Sample 3
Additional Compounds mean ***REDACTED***.
Sample 1Sample 2

Examples of Additional Compounds in a sentence

  • The Company may exercise such Opiant Option with respect to the Compounds by written notice to Aegis within 90 days of the completion of the Study for (i) the Compounds or (ii) the Additional Compounds.

  • EPA Should Expand the List of PFAS That Are Subject to Quarterly Sampling and Monitoring Requirements When Additional Compounds Are Detectable.

  • Examples of High Priority Chemicals with Persistence and Bioaccumulation Potentiala(See Table S3 of the Supporting Information for Additional Compounds) TABLE 1.

  • The parties further agree that, except to the extent specifically provided otherwise in this article, the arbitration shall be in accordance with the applicable rules of the American Arbitration Association then applying.

  • Lightlake has requested that Aegis transfer and Aegis wishes to transfer to Lightlake the Technology for the purpose of enabling Lightlake to conduct a feasibility study of the Compound and, potentially, the Additional Compounds, used with the Technology.

  • AlgorithmDescriptionNon‐SP 800‐56B compliant RSA Key Transport[IG D.9] RSA May be used by a calling application as part of a key encapsulation scheme.Key sizes: 4096 up to 16384 bits.MD5 within TLS[IG D.2] Table 8 – Non-Approved Cryptographic Functions for use in non-FIPS mode only.

  • Such reporting shall include, but not limited to, details of the costs incurred, reason for entertainment/hospitality, number of attendees, and whether attendees were MRC Staff or external persons.MRC must keep sufficient records to enable the correct calculation of its FBT liability.

  • The solvent was heated using the heating mantle and began to evaporate moving through the apparatus to the condenser.

  • Comprehensive Groundwater Sampling for Additional Compounds and Emerging Contaminants A comprehensive round of groundwater sampling will be performed at the existing groundwater monitoring wells during the Q3 2021 sampling event.

  • Notwithstanding the foregoing, unless the Parties otherwise agree in writing, the Compounds known to Targacept as of the Execution Date as [********], [********] and, [********], including any salt form, polymorph, crystalline form, Prodrug, metabolite (other than any such metabolite that is an Excluded Zone Compound), hydrate, solvate or formulation thereof, shall not be Additional Compounds.


More Definitions of Additional Compounds

Additional Compounds means any compound, the rights to use for Primary Indication are owned or controlled by Centaur and which Centaur intends to develop for the Primary Indication. Additional Compounds shall include such compounds and all pharmaceutically acceptable salts, esters, prodrugs, metabolites, precursors and other such forms thereof for use in treating the Primary Indication.
Sample 1Sample 2
Additional Compounds means any compound or formulation now or hereafter owned by the Company or in which the Company has any development, marketing or similar rights, other than the Compounds utilizing the Cytogen Technology or the Elan Technology.
Sample 1Sample 2
Additional Compounds mean CP57, CP78, CP66
Sample 1
Additional Compounds means a supplemental library specified in an sd file identified in Exhibit B and separate from compounds transferred under Section 2.1(a) that is sent to Avalon by ChemDiv with the written consent of Avalon.”
Sample 1
Additional Compounds has the meaning set forth in Section 6.2.2(b). ***Confidential Treatment Requested
Sample 1

Related to Additional Compounds

  • Additional Product means any Product identified as such in the Product Terms and chosen by Enrolled Affiliate under this Enrollment.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Additional Indication means any indication other than the Initial Indication.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Compounds means a small molecule HMT inhibitor.

  • Replacement Candidate means any Candidate Introduced by the Agency to the Client to fill the Engagement following the Introduction of another Candidate whose Engagement either did not commence or was terminated during the first 12 weeks of the Engagement;

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Development Milestone Event shall have the meaning set forth in Section 9.2(a).

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Additional Products means products, services and applications that are not part of the Services but that may be accessible, via the Admin Console or otherwise, for use with the Services.

  • Initial Indication means the treatment of Netherton Syndrome in humans in the Territory.

  • Replacement Product means electric generating capacity, capacity-related benefits, environmental attributes, Energy or other electric products from a generation resource other than the Facility that are provided or delivered to replace or substitute for Contract Capacity or Storage Capacity (or any Capacity-Related Benefit, Environmental Attribute, Other Electric Product, Contract Energy, or Storage Energy associated therewith), in each case, in whole or in part, pursuant to Section 4.6.

  • Exempt compound means the same as defined in Rule 2.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity:

  • Phase I Trial means a clinical trial of a Licensed Product in human patients conducted primarily for the purpose of determining the safety, tolerability and preliminary activity of the Licensed Product, including, without limitation, for determining the maximum tolerated dose, or optimal dose. For purposes of this Agreement, a Phase I trial shall specifically exclude a study in healthy volunteers.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Commercializing means to engage in Commercialization and “Commercialized” has a corresponding meaning.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.